IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner.
Müller S, Glaß M, Singh AK, Haase J, Bley N, Fuchs T, Lederer M, Dahl A, Huang H, Chen J, Posern G, Hüttelmaier S. · 2019
Read IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner. by Müller S, Glaß M, Singh AK, Haase J, Bley N, Fuchs T, Lederer M, Dahl A, Huang H, Chen J, Posern G, Hüttelmaier S. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6326824.txt.
Introduction
Müller and co-authors trace how the RNA-binding protein IGF2BP1 boosts a cancer gene program. Their study appeared in Nucleic Acids Research. IGF2BP1 appears in fetal tissue and returns in tumors. It binds the regulator SRF, which switches genes on. The team worked with cancer cells in the lab.
IGF2BP1 raised SRF levels in an m6A-dependent way. It shielded the SRF message from microRNA-driven decay. More SRF meant stronger activity at its target genes. Two targets, PDLIM7 and FOXK1, helped tumor cells grow and invade. A set of 35 linked genes marked poor survival. The pattern showed in ovarian, liver, and lung cancers. The authors name this network a shared driver of cancer growth.
Catalog record
| CREATOR | Müller S, Glaß M, Singh AK, Haase J, Bley N, Fuchs T, Lederer M, Dahl A, Huang H, Chen J, Posern G, Hüttelmaier S. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 75 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner By Simon Müller, Markus Glaß, Anurag K Singh, Jacob Haase, Nadine Bley, Tommy Fuchs, Marcell Lederer, Andreas Dahl, Huilin Huang, Jianjun Chen, Guido Posern, Stefan Hüttelmaier Published in: Nucleic Acids Research DOI: 10.1093/nar/gky1012 ABSTRACT Abstract The oncofetal mRNA-binding protein IGF2BP1 and the transcriptional regulator SRF modulate gene expression in cancer. In cancer cells, we demonstrate that IGF2BP1 promotes the expression of SRF in a conserved and N6-methyladenosine (m6A)-dependent manner by impairing the miRNA-directed decay of the SRF mRNA. This results in enhanced SRF-dependent transcriptional activity and promotes tumor cell growth and invasion. At the post-transcriptional level, IGF2BP1 sustains the expression of various SRF-target genes. The majority of these SRF/IGF2BP1-enhanced genes, including PDLIM7 and FOXK1, show conserved upregulation with SRF and IGF2BP1 synthesis in cancer. PDLIM7 and FOXK1 promote tumor cell growth and were reported to enhance cell invasion. Consistently, 35 SRF/IGF2BP1-dependent genes showing conserved association with SRF and IGF2BP1 expression indicate a poor overall survival probability in ovarian, liver and lung cancer. In conclusion, these findings identify the SRF/IGF2BP1-, miRNome- and m6A-dependent control of gene expression as a conserved oncogenic driver network in cancer. INTRODUCTION The mammalian IGF2 mRNA binding proteins (IGF2BPs; alias: VICKZ, CRD-BP, IMPs or ZBPs) family encompasses three RNA-binding proteins (RBPs) controlling the cytoplasmic fate of mRNAs in development, somatic cells and human diseases (1). Two members, IGF2BP1 and 3, are bona fide oncofetal proteins (1,2). They are abundant during development, expressed in some progenitor cells, barely observed in adult life but become upregulated or de novo synthesized in cancer (1,3–5). Recent studies indicate that IGF2BP1 has the most conserved ‘oncogenic’ role of the IGF2BP family in tumor-derived cells (6). The protein promotes a mesenchymal tumor cell phenotype characterized by altered actin dynamics, elevated migration, invasion, proliferation, self-renewal and anoikis resistance (7–9). Consistently, IGF2BP1 expression is associated with poor prognosis in various human cancers and the protein enhances the growth and metastasis of human tumor-derived cells in nude mice, as demonstrated for epithelial ovarian cancer (EOC) as well as hepatocellular carcinoma (HCC) derived tumor cells (6,10). This ‘oncogenic’ role of IGF2BP1 essentially relies on the impairment of mRNA decay. By associating with its target mRNAs, IGF2BP1 interferes with the degradation of target transcripts by endonucleases, as demonstrated for the MYC mRNA (11,12), or miRNA-directed decay, as shown for the vast majority of by now validated target mRNAs (6,9,13). Recent studies revealed that the association of IGF2BPs with target mRNAs, e.g. the MYC mRNA, is enhanced by the N6-methyladenosine (m6A) modification of target transcripts suggesting IGF2BPs as novel m6A-readers (14). Cross-linking immunoprecipitation (CLIP) analyses identified a plethora of candidate target mRNAs of IGF2BPs and revealed the 3′UTR as the mainly bound cis-element in associated transcripts (15–17). Although these studies indicate a substantial conservation of IGF2BP–mRNA association in tumor and stem cells, the phenotypic roles of IGF2BP homologs show a large variability in tumor cells derived from distinct cancers (6). The conserved phenotypic role of IGF2BP1 in tumor-derived cells suggests that the protein, in addition to promoting MYC synthesis, enhances additional oncogenic pathways not or barely affected by the other IGF2BP homologs. In this study, we identify the SRF-encoding (serum response factor) mRNA as a conserved target mRNA of IGF2BP1 in cancer. SRF controls gene expression in concert with two classes of regulators: ternary complex factors (TCFs: ELK1, 3 and 4) and myocardin-related transcription factors (MRTFA and MRTFB) (18). Transcriptomic analyses revealed that SRF-MRTF driven transcription modulates the expression of genes involved in cytoskeletal regulation, cell adhesion, migration and invasion (19–21). Although partially overlapping, SRF/TCF-dependent gene expression mainly affects genes modulating proliferation and growth factor responsiveness (20,22). The SRF/MRTF-dependent control of gene expression essentially relies on RhoGTPase-signaling and actin dynamics modulating the subcellular localization and activity of MRTFs in transcription (23,24). Transcriptional control by SRF/TCFs is regulated by Mitogen-activated protein kinase-signaling (MAPK-signaling) (18,25). Thus, in concert with MRTFs and TCFs, SRF serves as a central hub modulating tumor cell migration, invasion and metastasis as well as proliferation and tumor growth in a signaling- and cytoskeleton-dependent manner (26–28). Notably, recent studies indicate that SRF destabilizes cell identity, promotes cellular reprogramming to pluripotency and when overexpressed in mice even enhances a metaplasia-like phenotype in the pancreas (29). Here, we demonstrate that IGF2BP1 promotes SRF and SRF target genes at the post-transcriptional level suggesting it as a post-transcriptional enhancer of SRF itself as well as SRF-dependent gene expression in cancer cells. IGF2BP1 promotes SRF expression in a m6A-dependent manner by impairing the miRNA-directed downregulation of the SRF mRNA. In addition, IGF2BP1 enhances the expression of SRF-induced target genes at the post-transcriptional level. In cancer, the SRF-IGF2BP1 directed enhancement of gene expression promotes an ‘aggressive’ tumor cell phenotype and is associated with poor prognosis. MATERIALS AND METHODS Plasmids and cloning Information on cloning strategies including vectors, oligonucleotides used for polymerase chain reaction (PCR) and restrictions sites are summarized in Supplementary Table ST5. All constructs were validated by sequencing. ChIP, RIP and RT-qPCR Chromatin immunoprecipitation (ChIP) experiments were performed essentially as described previously (30). In brief, ∼2.5 × 107 ES-2 cells were treated with formaldehyde, quenched and harvested in lysis buffer (10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.9; 7.2 mM KOH; 150 mM KCl; 5 mM MgCl2; 0.5% NP-40; protease inhibitors). Nuclei were enriched by centrifugation and lysed in ChIP-buffer (50 mM Tris-Cl, pH 8.0; 10 mM ethylenediaminetetraacetic acid (EDTA); 1% sodium dodecyl sulphate (SDS); protease inhibitors) before chromatin was sheared by sonification. For ChIP, 25 μg of sheared chromatin was incubated with control (anti-IgG, Abcam ab171870) or anti-SRF (NEB 5147) antibodies overnight in dilution buffer (10 mM Tris-Cl, pH 8.0; 150 mM NaCl; 1 mM EDTA; 0.1% SDS; 1% Triton X-100; protease inhibitors). Upon extensive washing, chromatin was eluted in elution buffer (50 mM Tris-Cl, pH 8.0; 10 mM EDTA; 1% SDS), treated with Proteinase K and cross-linking was reversed overnight. DNA was finally eluted using the WIZARD®SV Gel & PCR Clean-Up System (Promega A9281) according to the manufacturer’s protocol and analyzed by quantitative real-time PCR (qPCR). RNA immunoprecipitation (RIP) and quantitative RT-PCR analyses were performed essentially as recently described (6). Primers are summarized in Supplementary Table ST5. Northern and western blotting Northern blotting of small RNAs and semi-quantitative infrared western blotting were performed as recently described (9). Probes and antibodies are summarized in Supplementary Tables ST5 and ST7. Luciferase reporter assays Promoter reporter assays were performed using the MRTF-specific 3.DA reporter (24) and a TCF-dependent reporter containing 500 bp of the murine Egr1 promoter cloned into pGL3 and the pRL-tk plasmid (kind gift from Bernd Knöll, Ulm University, Germany). Cells were retransfected with siRNAs using RNAiMax for 24 h before reporter transfection with polyethylenimine and harvested for analysis the following day, as described previously (31). Firefly luciferase activity was normalized to fluorescence of co-transfected EGFP (BMG Labtech Clariostar microplate reader) and was shown relative to the control siRNA transfection. For the analysis of miRNAs targeting the SRF 3′UTR, 48-nt long regions of the SRF 3′UTR comprising predicted miRNA targeting sites (MTSs) were cloned 3′ to the firefly luciferase open reading frame (pmirGLO, Promega). Luciferase reporter analyses were performed as previously described (9). The activities of firefly and renilla luciferases were